James Glover has been named CEO of Beckman Coulter, having served as the company’s interim CEO since Aug. 2003.

Glover joined Beckman Coulter in 1983. Since the beginning of 2003, he has served as vice president, controller, and chief accounting officer. While at the company, he has led its capital restructuring and elimination of over $450 million in debt, as well as its risk management program and other efforts related to bond ratings and tax rate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.